Savara (NASDAQ:SVRA) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Savara (NASDAQ:SVRA) from a sell rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Savara presently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Savara Stock Down 1.4%

Shares of NASDAQ:SVRA opened at $5.00 on Friday. The firm has a market capitalization of $1.03 billion, a PE ratio of -8.62 and a beta of 0.25. Savara has a 1 year low of $3.34 and a 1 year high of $7.01. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13. The firm’s 50-day moving average is $5.44 and its two-hundred day moving average is $5.43.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Analysts predict that Savara will post -0.61 EPS for the current year.

Institutional Investors Weigh In On Savara

A number of large investors have recently modified their holdings of the company. Principal Financial Group Inc. purchased a new stake in shares of Savara during the 1st quarter worth $57,000. Sequoia Financial Advisors LLC purchased a new stake in Savara during the 2nd quarter worth about $69,000. E Fund Management Co. Ltd. acquired a new position in shares of Savara during the 2nd quarter worth about $77,000. Sanctuary Advisors LLC acquired a new position in shares of Savara during the 2nd quarter worth about $87,000. Finally, Inceptionr LLC purchased a new position in shares of Savara in the 1st quarter valued at about $84,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

About Savara

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company’s primary focus is autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which abnormal accumulation of surfactant in the lungs can impair breathing and oxygen exchange.

Savara’s lead product candidate is molgramostim, an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is designed to help restore the function of pulmonary alveolar macrophages, the immune cells responsible for clearing excess surfactant from the lungs.